With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

What are the Monster Hunter Wilds monsters? The best way for any hunter to prepare for a trip to the Forbidden Lands is to get familiar with all the monsters that call it home. Capcom has already ...

Fifteen-year-old Dominic Henriquez from Prosper, Texas, is bringing hope to boys like him who live with Hunter syndrome, a rare genetic disorder that primarily affects males. Dominic’s journey ...

The heat sources can cause what is known as toasted skin syndrome, which can leave a patterned mark on your skin from the repeated exposure to the heat. A TikTok about toasted skin syndrome went ...

Hunter syndrome affects over 2,000 individuals, primarily males, in commercially accessible regions. With analysts maintaining a Strong Buy consensus and the company maintaining a healthy ...

When is the Monster Hunter Wilds release date? Following the much-lauded migration 0f Monster Hunter onto PC in recent years, we’re sharpening our blades in preparation for the next installment ...

We are grateful to the FDA for recognizing the potential of tividenofusp alfa as a meaningful treatment option for individuals with Hunter syndrome. We look forward to continued collaboration with ...

For better visualization, your dermatologist may use a magnifying tool such as a dermatoscope, she says, and if there is a concerning lesion where a skin biopsy test is recommended, your ...